- Home
- SOTK vs ESLA Comparison
SOTK vs ESLA Comparison
Compare SOTK & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- ESLA
- Stock Information
- Founded
- SOTK 1975
- ESLA 2021
- Country
- SOTK United States
- ESLA United States
- Employees
- SOTK N/A
- ESLA N/A
- Industry
- SOTK Industrial Machinery/Components
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOTK Technology
- ESLA Health Care
- Exchange
- SOTK Nasdaq
- ESLA Nasdaq
- Market Cap
- SOTK 52.1M
- ESLA 48.9M
- IPO Year
- SOTK 1987
- ESLA N/A
- Fundamental
- Price
- SOTK $3.82
- ESLA $1.89
- Analyst Decision
- SOTK Hold
- ESLA Strong Buy
- Analyst Count
- SOTK 1
- ESLA 1
- Target Price
- SOTK N/A
- ESLA $16.00
- AVG Volume (30 Days)
- SOTK 22.6K
- ESLA 407.5K
- Earning Date
- SOTK 01-12-2026
- ESLA 11-12-2025
- Dividend Yield
- SOTK N/A
- ESLA N/A
- EPS Growth
- SOTK 6.63
- ESLA N/A
- EPS
- SOTK 0.10
- ESLA N/A
- Revenue
- SOTK $20,607,030.00
- ESLA N/A
- Revenue This Year
- SOTK $2.67
- ESLA N/A
- Revenue Next Year
- SOTK $8.20
- ESLA N/A
- P/E Ratio
- SOTK $40.53
- ESLA N/A
- Revenue Growth
- SOTK N/A
- ESLA N/A
- 52 Week Low
- SOTK $3.23
- ESLA $0.73
- 52 Week High
- SOTK $6.05
- ESLA $3.15
- Technical
- Relative Strength Index (RSI)
- SOTK 30.79
- ESLA 45.57
- Support Level
- SOTK $3.90
- ESLA $1.50
- Resistance Level
- SOTK $4.08
- ESLA $1.99
- Average True Range (ATR)
- SOTK 0.18
- ESLA 0.32
- MACD
- SOTK -0.08
- ESLA -0.11
- Stochastic Oscillator
- SOTK 11.35
- ESLA 20.53
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.